Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirtris Pharmaceuticals has reported that one of its new chemical entity SIRT1 activators lowered plasma glucose and improved insulin sensitivity in a pre-clinical model of Type 2 diabetes as well as or better than sitagliptin, a DPP-4 inhibitor.
Subscribe to our email newsletter
In addition, in an intraperitoneal glucose tolerance test, Sirtris’s SIRT1 activator was shown to control glucose excursion as well as sitagliptin in this pre-clinical model of Type 2 diabetes. In contrast to DPP-4 inhibitors, which lower glucose, SIRT1 activation appears to both lower glucose and also sensitize to insulin in these models.